Brain Cancer Articles | Page 2

Onartuzumab Shows No Additional Benefit When Combined With Bevacizumab in GBM
The addition of onartuzumab to bevacizumab did not provide any increased clinical benefit in the treatment of patients with recurrent glioblastoma multiforme.
Tumor-Treating Fields Make Significant Impact in GBM

It’s not often that oncologists get to be the first to utilize cutting-edge technology.

IDO Inhibitors Among Immunotherapy Strategies Under Study in Glioblastoma
The concept of using immunotherapies to treat patients with glioblastoma multiforme is gaining ground among researchers who are interested not only in evaluating checkpoint blockade agents that have proved effective in other tumor types but also in exploring novel targets.
Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields (TTFields) device beyond its current FDA-approved use in recurrent grade IV glioblastoma.
Nivolumab/Radiotherapy Combo Well-Tolerated in Newly Diagnosed GBM
Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.
Durvalumab Shows Durable Activity in Recurrent GBM
The PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-naïve patients with recurrent glioblastoma multiforme. 
AG-120 Shows Early Efficacy in IDH1-Mutant Glioma
Treatment with AG-120 at an established dose of 500 mg induced a stable disease rate of 83% and a minor response rate of 9% for patients with non-enhancing IDH1-mutated glioma.
Optune Survival Benefit in GBM Sustained With Long-Term Data
Updated data from the phase III EF-14 study showed that adding Optune to temozolomide improved overall survival by 4.8 months compared with temozolomide alone in patients with newly diagnosed glioblastoma multiforme.
Pembrolizumab Shows Durable Benefit for PD-L1-Positive Recurrent GBM
Pembrolizumab had a 6-month progression-free survival rate of 44% and a manageable safety profile for patients with recurrent PD-L1-positive glioblastoma multiforme.
Checkpoint Inhibitors Show Promise in Glioblastoma
Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.
Publication Bottom Border
Border Publication